A 63-year-old man with heart failure with reduced ejection fraction (LVEF 30%) is already on an ACE inhibitor and evidence-based beta-blocker. According to the 2021 CCS heart failure update, which additional therapy should routinely be added to optimise guideline-directed medical therapy, assuming no contraindication?